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   Abstract 
Background
In 2009 Malawi introduced a new protocol to screen potential 
blood donors for anaemia, using the WHO Haemoglobin Colour 
Scale (HCS) for initial screening. Published studies of  the accuracy 
of  the HCS to screen potential blood donors show varying levels 
of  accuracy and opinion varies whether this is an appropriate 
screening test. The aim of  the study was to assess the validity 
of  the HCS, as a screening test, by comparison to HemoCue in 
potential blood donors in Malawi.
Study design and methods 
This was a blinded prospective study in potential blood donors 
aged over 18 years, at Malawi Blood Transfusion Service in 
Blantyre, Malawi. Capillary blood samples were analysed using the 
HCS and HemoCue, independent of  each other. The sensitivity 
and specificity of  correctly identifying ineligible blood donors 
(Hb≤12g/dL) were calculated.
Results  
From 242 participants 234 (96.7%) were correctly allocated and  8 
(3.3%), were wrongly allocated on the basis of  the Haemoglobin 
Colour Scale (HCS) compared to HemoCue, all were subjects that 
were wrongly accepted as donors when their haemoglobin results 
were ≤12.0g/dL. This gave a sensitivity of  100% and specificity 
of  96.7% to detect donor eligibilty. The negative predictive value 
of  the HCS was 100% but the positive predictive value to identify 
ineligible donors on the basis of  anaemia was only 20%.
Conclusions
Initial screening with the HCS correctly predicts eligibility for 
blood donation in the majority of  potential blood donors at 
considerable cost saving compared with use of   HemoCue as the 
first line anaemia screening test, however, by this method a small 
number of  anaemic patients were allowed to donate blood.
Introduction
Anaemia is a major public health concern in Malawi and most 
low and middle income countries. A 1993-2005 World Health 
Organisation study estimated that it affected over 1620 
million people, representing 24.8% of  the world population.1 
Despite the high prevalence rates, detection of  the condition 
remains a problem in the developing world with most cases 
diagnosed clinically. Clinical diagnosis has a sensitivity of  29-
44% and a specificity of  81-89%, limiting its usefulness in 
diagnosing anaemia.2 The Haemoglobin Colour Scale (HCS) 
was developed in 1995 as an inexpensive, simple alternative 
for assessing anaemia.3,4 It does not aim to compete with a 
haemoglobinometer in the laboratory, but it is intended for 
use when the latter is not available or practical. The HCS 
uses a strip of  chromatography paper and a standard colour 
chart. The method relies on comparing the colour of  a 
drop of  blood absorbed onto chromatography paper with 
standard colours on a laminated card, varying from pink to 
dark red. These colours correspond to haemoglobin (Hb) 
levels of  4, 6, 8, 10, 12, and 14 g/dl. Intermediate shades can 
be identified, allowing haemoglobin levels to be judged to 1 
g/dL.3 
Laboratory and community studies have assessed the accuracy 
of  the HCS for diagnosing anaemia, but controversy over its 
validity and usefulness remains.5-8 A meta-analysis, including 
validation studies conducted in the laboratory and in the field 
(ie. ‘real life’), has  shown that the sensitivity of  the HCS to 
detect any anaemia is approximately 75-97% with a specificity 
of  41-98%. The sensitivity and specificity are increased for 
severe anaemia (<7 g/dL or <6 g/dL in different studies).8,9 
Laboratory based studies show a far greater accuracy than 
real life clinical studies, but accuracy in clinical settings can 
be improved after training.8 The accuracy varies depending 
on the prevalence of  anaemia in the population, being more 
accurate in populations with a higher prevalence.9 
Screening of  blood donors to exclude those who are ineligible 
due to anaemia is a prerequisite of  any blood donation 
service. Many different methods of  donor screening can 
be used but in resource poor countries low cost methods 
are essential. In 2001 Lewis and Emmanuel published a 
validation of  the HCS as a screening test for blood donor 
eligibility, showing it to be highly sensitive and specific and 
superior to the semi-quantitative copper sulphate method 
which had been widely used since the 1950s.10 The Malawi 
Blood Transfusion Service (MBTS) is the national blood 
service for Malawi which collects about 50,000 donor whole 
blood units per year. Since 2009 the MBTS has used the HCS 
to screen all blood donors to determine their eligibility for 
blood donation and to detect those that will need additional 
testing with  HemoCue before their eligibility can be decided. 
The SOP stipulates that all blood donors are screened with 
HCS. Those with Hb  <12g/dL are deferred for blood 
donation, those with Hb >12g/dL are accepted for blood 
donation, those with Hb =12g/dL are referred for testing 
with  HemoCue and are accepted for donation if  the Hb is 
≥12.5g/dL. 
Validation of  the use of  HCS in a real world setting, using 
our own staff  following the local protocol for pre-donation 
anaemia screening, is necessary to ensure that ineligible 
individuals are not being accepted to donate blood and 
that eligible potential blood donors are not being rejected 
unnecessarily. The objective of  the study was to assess the 
accuracy of  the Haemoglobin Colour Scale by comparison 
to results obtained using a  HemoCue in a donor population, 
to assess the validity of  the MBTS protocol of  using the 
HCS and  HemoCue in screening for anaemia in potential 
blood donors.
Materials and Methods
A convenience sample of  242 potential blood donors aged 
19-65 years of  age were independently tested with both 
HCS (Copack GmbH, Germany) and  HemoCue (HemoCue 
Hemoglobin system, HemoCue AB, Ängelholm, Sweden) 
at the MBTS blood donor clinics in Blantyre during the 
month of  January. The investigators were trained to use 
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the validated HemoCue machines by MBTS staff. Routine 
capillary blood samples were collected by the Malawi Blood 
transfusion staff  through a skin puncture and measured 
using the Haemoglobin Colour Scale for their decision 
making on the eligibility of  the donors. On any day 2 MBTS 
staff  are on duty screening donors and the team changes 
every 3 days so at least 4 MBTS staff  were involved in taking 
HCS readings. The investigators also collected finger prick 
samples from the same donors and measured the sample 
using the HemoCue. The HemoCue results were collected 
independent of  the HCS results and the MBTS staff  were 
not informed of  the HemoCue result. The investigators did 
not have prior knowledge of  the HCS results. The donor had 
an ID number which was recorded by the donor staff  and the 
investigators so that the blinding was achieved.  Thereafter, 
the different set of  results was compared.
Statistical Analysis
Sensitivity and specificity are terms used to evaluate a clinical 
test. Sensitivity measures the proportion of  actual positives. 
Specificity measures the proportion of  negatives which are 
correctly identified. The sensitivity, specificity and predictive 
values of  the HCS for identifying ineligible blood donors 
were calculated. Bias and limits of  agreement (LOA) were 
calculated, using the method of  Altman and Bland, for the 
complete dataset and after excluding those with Hb >15g/
dL on HemoCue as the upper limit of  HCS is 14g/dL.11The 
study was approved by the College Of  Medicine Research 
and Ethics Committee (COMREC).
Results
Measurements were obtained for 242 donors. Table 1 shows 
the comparison of  the HCS results to those of  HemoCue. 
On HCS screening there were 197 subjects (81%) correctly 
identified as eligible to donate blood and 2 subjects (0.8%) 
were correctly identified as ineligible to donate. Thirty five 
subjects (14.5%) had borderline results (Hb=12g/dL) by 
HCS and, according to the MBTS SOPs would have gone on 
to have HemoCue to determine their eligibility for donation. 
For calculation of  sensitivity and specificity these 35 have 
been excluded. Eight subjects (3%) were wrongly assessed to 
have Hb >12 g/dL and were wrongly allocated as eligible to 
donate by HCS. The Hb values in these subjects were; 8.6, 
10.0, 11.2, 11.4, 11.6, 11.8, 11.8 and 12.0 g/dL. No subjects 
were wrongly excluded as donors.
The sensitivity of  the HCS to detect those ineligible for 
donation was 100% (2/2) and the specificity was 96.1% 
(197/205). The positive predictive value (PPV) of  the HCS 
to detect ineligible donors was 20% (2/10) and the negative 
predictive value (NPV) was 100% (197/197). 
Overall 50 results (20.7%) showed a discrepancy of  >1g/
dL between HCS and  HemoCue  (excluding those with Hb 
>15g/dL on  HemoCue as the upper limit of  HCS is 14g/dL). 
In the majority this did not affect eligibility allocation.  The 
extent of  the discrepancy between the methods is reflected 
in the limits of  agreement. Figure 1 shows the Bland-Altman 
plots for the complete and restricted dataset. For samples 
with Hb≤15g/dL the bias (95% limits of  agreement) was 
estimated to be 0.27 (-1.82, 2.37) ie 95% of  HCS values are 
expected to lie between 2.37 g/dL below and 1.82 g/dL 
above the  HemoCue value.
Table 1   Haemoglobin Colour Scale and HemoCue results by 
haemoglobin-based categories. *These 35 subjects require a further 
confirmatory test (HemoCue) to determine donor eligibility according 
to the MBTS SOP and would have been correctly allocated after the 
second test.
Figure 1   Bland-Altman plots for Haemoglobin Colour Scale com-
pared with the reference (a) for complete data set (b) for blood samples 
in which  HemoCue≤15g/dL
Discussion
These results demonstrate the high sensitivity, specificity 
and negative predictive values, but relatively poor positive 
predictive value of  the HCS as a screening tool for blood 
donor eligibility when used according to the Malawi BTS 
protocol. Misallocation was on the side of  accepting ineligible 
donors. The risk of  this is two-fold; firstly an anaemic donor 
may be made even more anaemic through blood donation. 
This may have significant consequences, eg for the subject 
in our survey with an Hb of  8.6g/dL who was allowed to 
donate. This may worsen the anaemia and deny them the 
opportunity to be diagnosed with anaemia and investigated 
and managed appropriately. Secondly the recipient of  the 
blood may receive fewer red cells than was expected by a 
standard transfusion.
Published evaluations of  the use of  the HCS as part of  a 
screening protocol prior to blood donation have shown 
mixed results. One study from India investigated HCS as a 
predonation screening test. The Hb was measured using HCS 
in the laboratory on venous whole blood and compared to 
the same sample measured on an automated analyser. Similar 
to our own study they found that in 23% of  samples the 
Hb measured by HCS lay > 1g/dL from the gold standard 
value.12 The sensitivity of  HCS was reported as 87% and 
specificity as 82%, for diagnosing anaemia, with limits of  
agreement from -4.7 to +5.6g/dL, but it is not clear how 
many donors were incorrectly allocated as a result of  this. 
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The authors concluded that HCS is not a good screening 
tool for blood donors and recommended that copper 
sulphate screening was more accurate. Conversely a study 
from Indonesia found that HCS was superior to the copper 
sulphate test for donor screening.13 Sawant and colleagues 
in India compared the HCS to an autoanalyser in subjects 
that had already been rejected for donation, on the basis 
of  anaemia.14 They found the sensitivity and specificity of  
HCS to be 97% and 93% respectively and recommended 
that HCS should be used for predonation screening. Finally 
a study that looked at randomly selected blood samples in 
a UK laboratory found that in 46% of  samples, the Hb 
value with the HCS lay more than 1g/dL from the value 
with an autoanalyser and gave limits of  agreement from 
-3.5 to +3.1 g/dL. Despite this the HCS performed better 
than the copper sulphate test in the same setting.15 All of  
these studies were methodologically different to ours, for 
example capillary samples may give higher Hb values that 
venous blood16 and most were conducted in the laboratory, 
rather than in a blood donor clinic. In our hands the HCS 
performed well as a screening tool for donor eligibility and 
gave limits of  agreement better than those reported above.
In the Malawi Blood Transfusion Service the cost of  
consumables for HCS testing is less than a third of  those 
for HemoCue testing (US$0.15 vs US$0.53). The MBTS 
screens approximately 50,000 potential donors per annum. 
According to our survey 14.5% of  them will need a second 
test, HemoCue to determine eligibility. Based on current 
prices the cost of  using HCS for primary screening, followed 
by  HemoCue, according to current Malawian practice is 
$11,342.5 per annum as compared to $26,500 if   HemoCue 
was used for initial screening. It would be interesting and 
useful to carry out a more detailed cost benefit analysis of  
the MBTS approach but sufficient economic data was not 
available.
The HCS does have limitations. It is more operator dependent 
than HemoCue. This study was conducted at a time MBTS 
was experiencing a high staff  turn over due to uncompetitive 
salaries. To address this MBTS undertakes regular, annual 
staff  training to maintain high standards of  accuracy. It also 
only grades haemoglobin values within 1g/dL and does not 
exceed 14g/dL, however, for the purpose of  blood donor 
screening this may not matter. Our study also had limitations. 
The observations were made at a single donor centre. It is 
necessary to repeat the survey at other centres and with other 
staff  to see if  similar levels of  sensitivity and specificity are 
obtained. A more detailed economic evaluation of  current 
practice is also needed including a comparison to the copper 
sulphate test.
Blood donation is life-saving. A recent study of  104 
transfusions at a district hospital in Malawi showed that the 
average Hb of  recipients prior to transfusion was 4.8g/dL. 
Fifty seven per cent of  recipients were children and 17% 
pregnant women17. The study also showed that, at the time of  
the survey, blood was available within 1 hour of  requisition. 
Our survey suggests that, when used with HemoCue, the 
Haemoglobin Colour Scale allows for implementation of  
an acceptable donor eligibility screening protocol which 
facilitates donation to such a vital service.
In conclusion we have demonstrated that our current 
practice of  initial screening with the Haemoglobin Colour 
Scale correctly predicts eligibility for blood donation in the 
majority of  potential blood donors at considerable cost 
saving compared with direct use of  HemoCue, however, it 
should be remembered that by this method a small number 
of  anaemic patients were allowed to donate blood. 
Acknowledgements 
We are extremely grateful to the nursing staff  at the Malawi 
Blood Transfusion Services head office in Blantyre for 
their support and cooperation during data collection. The 
College of  Medicine Research Support committee funded 
the project. 
References
1. WHO, Worldwide prevalence on anaemia 1993-2005.  http://www.
who.int/vmnis/anaemia/prevalence/summary/anaemia_status_sum-
mary/en/index.html (Accessed 19th september 2013)
2. Chalco JP, Huicho L, Alamo C, et al.  Accuracy of clinical pallor in 
the diagnosis of anaemia in children: a meta-analysis. BMC Pediatri 
Stott GJ, Lewis SM. A simple and reliable method for estimating hae-
moglobin. Bull World Health Organ 1995;73:369–73.
4. Lewis S M, Stott G J, Wynn K J. An inexpensive and reliable 
new haemoglobin colour scale for assessing anaemia J Clin Pathol 
1998;51:21–24
5. Montresor A, Ramsan M, Khalfan N, et al. Performance of the Hae-
moglobin Colour Scale in diagnosing severe and very severe anaemia 
Trop Med Int Health 2003; 8: 619–624
6. Lindblade KA, Mwololo K, van Eijk AM, et al. Evaluation of the 
WHO Haemoglobin Colour Scale for diagnosis of anaemia in children 
and pregnant women as used by primary health care nurses and com-
munity health  workers in western Kenya 2006 Trop Med Int Health; 
11: 1679–1687
7. Aldridge C, Foster HME, Albonico M, et al. Evaluation of the diag-
nostic accuracy of the Haemoglobin Colour Scale to detect anaemia in 
young children attending primary healthcare clinics in Zanzibar Trop 
Med Int Health 2012;17: 423–429
8. Ingram CF, Lewis SM. Clinical use of WHO haemoglobin colour 
scale:validation and critique J Clin Pathol 2000;53:933–937
9. Critchley J, Bates I. Haemoglobin colour scale for anaemia diag-
nosis where there is no laboratory: a systematic review. International 
Journal of Epidemiology 2005;34: 1425–1434.
10. Lewis SM,  Emmanuel J.  Validity of the haemoglobin colour scale 
in blood donor Screening Vox Sanguinis 2001 80  28–33
11. Bland JM, Altman DG. Statistical methods for asessing agreement 
between two methods of clinical measurement. Lancet 1986; 1:307-10
12. Tondon R, Verma A, Pandey P, et al. Quality evaluation of four 
hemoglobin screening methods in a blood donor setting along with 
their comparative cost analysis in an Indian scenario. Asian J Transfus 
Sci. 2009 July; 3(2): 66–69.
13. Timan IS, Tatsumi N, Aulia D, et al. Comparison of haemoglobi-
nometry by WHO Haemoglobin colour scale and copper sulphate 
against haemoglobincyanide reference method. Clin Lab Haematol. 
2004;26:253–8
14. Sawant RB, Bharucha ZS, Rajadhyaksha SB. Evaluation of 
hemoglobin of blood donors deferred by the copper sulphate method 
for hemoglobin estimation Transfusion and Apheresis Science 36 2007 
143–148
15. Paddle JJ. Evaluation of the Haemoglobin colour Scale and com-
parison with the  HemoCue haemoglobin assay. Bull World Health 
Organ. 2002;80:813–6
16.  Radtke H, Polat G, Kalus U, et al. Hemoglobin screening in 
prospective blood donors: Comparison of different blood samples and 
different quantitative methods. Transfus Apher Sci. 2005;33:31–5
17. Bugge HF, Karlsen NC, Oydna E, et al. A study of blood trans-
fusion services at a district hospital in Malawi. Vox Sang. 2013 
Malawi Medical Journal; 26 (2) 30-33 March 2014 Validation of the haemoglobin  33
Jan;104(1):37-45.
